Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
By P. Moreau, H. Pylypenko, S. Grosicki, Ievgenii Karamanesht, X. Leleu, M. Grishunina, G. Rekhtman, Z. Masliak, T. Robak, Anna V Shubina and 9 more. The Lancet Oncology, 2011
937 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/d548a51c524313aa6d1bec5ba39d0127e8a870b3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “However, the neurotoxicity of bortezomib can be greatly diminished by administering bortezomib once a week instead of twice-weekly,(59,60) and by administering the drug subcutaneously instead of the intravenous route.(99) The once-weekly subcutaneous bortezomib schedule (Table 6) has made seri-”
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012, neutral): “Median creatinine clearance, mL/min (range) 70 (16-203)”
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, neutral): “Neutropenia‡ 118 (33) 64 (18) 17 (5) 111 (31) 63 (18) 22 (6)”
- Chemotherapy-Induced Peripheral Neuropathy: A Current Review (2017, background): “Recently, it was discovered that subcutaneous delivery decreases the likelihood and severity of the neuropathy.(3) A small proportion of patients receiving bortezomib develop a severe polyradiculoneuropathy, which appears to be immunemediated.”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “administering the drug subcutaneously instead of the intravenous route.(103) The once-weekly subcutaneous bortezomib schedule (Table 6) has made serious neuropathy an uncommon problem, and has made regimens such as VRd, VCd, and VTd much more tolerable.”